| | | | | | What you need to know about the coronavirus today | | | "So far, so good" on vaccine Drugmaker AstraZeneca said on Thursday that positive data was coming in on its vaccine for COVID-19, already in large-scale human trials and widely seen as the front-runner in the race to produce a shot against the novel coronavirus.
AstraZeneca has already reached deals with countries to make more than 2 billion doses of its COVID-19 vaccine, developed in partnership with the University of Oxford, and says it could be approved by the end of this year.
Isolate for longer Anyone who tests positive or shows symptoms of COVID-19 in Britain will have to self-isolate for 10 days instead of the previous seven, based on a low but tangible possibility that people could remain infectious for longer.
"In symptomatic people COVID-19 is most infectious just before, and for the first few days after symptoms begin," the UK chief medical officers said in a statement on Thursday.
A death a minute One person in the United States died about every minute from COVID-19 on Wednesday as 1,461 new deaths were recorded, the highest one-day increase since 1,484 on May 27, according to a Reuters tally.
U.S. coronavirus deaths are rising at their fastest rate in two months.
Spikes in infections in Arizona, California, Florida and Texas this month have overwhelmed hospitals. The rise has forced states to make a U-turn on reopening economies that were restricted by lockdowns in March and April to slow the spread of the virus.
"Recession of a century" The German economy contracted at its steepest rate on record in the second quarter as consumer spending, company investment and exports all collapsed during the peak of the COVID-19 pandemic, wiping out nearly 10 years of growth.
Gross domestic output in Europe's largest economy shrank by 10.1% quarter-on-quarter from April to June after a revised 2.0% contraction in the first three months of the year. | | | | | | Reuters reporters and editors around the world are investigating the response to the coronavirus pandemic.
We need your help to tell these stories. Our news organization wants to capture the full scope of what’s happening and how we got here by drawing on a wide variety of sources. Here’s a look at our coverage.
Are you a government employee or contractor involved in coronavirus testing or the wider public health response? Are you a doctor, nurse or health worker caring for patients? Have you worked on similar outbreaks in the past? Has the disease known as COVID-19 personally affected you or your family? Are you aware of new problems that are about to emerge, such as critical supply shortages?
We need your tips, firsthand accounts, relevant documents or expert knowledge. Please contact us at coronavirus@reuters.com.
We prefer tips from named sources, but if you’d rather remain anonymous, you can submit a confidential news tip. Here’s how. | | | | | | | | | Top Stories | As President Donald Trump’s support in the U.S. suburbs erodes amid concerns about his handling of the coronavirus pandemic, he has returned to a familiar campaign theme: trying to scare voters away from backing Democrat Joe Biden in November.
From deploying federal agents to confront protesters in cities such as Portland, Oregon, to releasing ads portraying a lawless and dangerous America under a Biden presidency, Trump has positioned himself as the candidate who will keep the country safe. | | | | China’s ambassador to London said on Thursday that the United States was trying to trigger a new Cold War with the Communist state because it was searching for a scapegoat ahead of the U.S. presidential election in November.
“It is not China (that has) become assertive. It’s the other side of the Pacific Ocean who want to start new Cold War on China, so we have to make response to that,” China’s ambassador to London Liu Xiaoming told reporters. “We have no interest in any Cold War, we have no interest in any war.” | | | COVID Science | CanSino Biologics, one of many companies worldwide trying to develop a coronavirus vaccine, needs to conduct late-stage trials overseas if it is to stay in the race, experts say, but it has yet to announce another country willing to help.
With other countries pushing ahead with their own tests and deepening tensions with the United States posing a challenge to international collaboration, time is not on its side. | | | | | | | | | Top Stories on Reuters TV | | | | | | | |